Tect2 Inhibitors
Tect2 inhibitors encompass a variety of compounds that indirectly decrease the activity of Tect2 through diverse signaling pathways. LY294002 and wortmannin, for instance, are potent PI3K inhibitors that would lead to reduced activation of Akt, a kinase that is often essential for the function of a myriad of proteins, including Tect2, by dampening downstream signaling cascades. Similarly, U0126 and PD98059 exert their effects by targeting the MEK enzymes in the MAPK/ERK pathway, a pathway that is frequently implicated in cellular proliferation and differentiation signals which could be necessary for Tect2 activity. The inhibition of these enzymes would therefore result in a decrease in ERK activation, potentially leading to diminished Tect2 function.
Further indirect inhibition of Tect2 can be observed with compounds like SB203580 and SP600125, which target p38 MAPK and JNK, respectively. Such inhibition can alter the stress response and other cellular processes that might be vital for the regulation of Tect2 activity. Rapamycin inhibits mTOR signaling, which could be crucial if Tect2 is part of growth andproliferation pathways. PP2 and dasatinib, by inhibiting Src family kinases, could diminish Tect2 activation if it is contingent upon signaling through these kinases. Bortezomib's role in inhibiting proteasomal degradation could result in the stabilization of proteins that negatively regulate Tect2, leading to its functional inhibition. Go6983 suppresses the activity of PKC, which, if involved in the activation of Tect2, would result in its decreased activity upon inhibition of PKC signaling. Lastly, palbociclib's inhibition of CDK4/6 might halt cell cycle progression, which could be a necessary process for Tect2 function, thereby indirectly leading to its inhibition.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3Ks). Since PI3Ks are involved in the activation of Akt, inhibiting these kinases leads to a reduction in Akt phosphorylation and activity. If Tect2 function is Akt-dependent, LY294002 would indirectly inhibit Tect2 by reducing the necessary Akt signaling that contributes to Tect2 activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, wortmannin binds irreversibly to PI3K, preventing Akt activation. Inhibition of this pathway would lead to decreased Tect2 activity if Tect2 relies on PI3K-Akt signaling for its functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound inhibits p38 MAPK, which is involved in stress responses. If Tect2 activity is modulated by p38 MAPK signaling, then inhibition of this kinase by SB203580 would result in decreased Tect2 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
An inhibitor of JNK, which is part of another MAPK pathway. If Tect2 operates downstream of JNK signaling, SP600125 would indirectly inhibit Tect2 by blocking JNK activity and thus the signaling required for Tect2's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can suppress the mTORC1 complex, which is involved in cell growth and proliferation. If Tect2 is regulated by mTOR signaling, rapamycin would inhibit Tect2 by reducing mTORC1 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A Src family kinase inhibitor. If Tect2 is activated by Src kinase signaling, PP2 would inhibit Tect2 indirectly by inhibiting Src family kinases and thereby reducing Tect2 activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK, which acts in the MAPK/ERK pathway. If Tect2 requires ERK signaling for its function, PD98059 would inhibit Tect2 by preventing MEK from activating ERK. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that prevents the degradation of proteins tagged for destruction. If Tect2 is regulated by proteasomal degradation, bortezomib could lead to an accumulation of negative regulators of Tect2, thereby indirectly inhibiting its activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A BCR-ABL and Src family kinase inhibitor that could inhibit Tect2 if its activity is associated with these kinases. By inhibiting Src kinases, dasatinib would reduce Tect2 activation. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
A protein kinase C (PKC) inhibitor. If Tect2 is activated downstream of PKC, Go6983 would inhibit Tect2 function by interfering with PKC signaling. | ||||||